Cargando…
Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) refers to chronic progressive fibrotic interstitial pneumonia. It is called a “tumor-like disease” and cannot be cured using existing clinical drugs. Therefore, new treatment options are urgently needed. Studies have proven that ferroptosis is closely related to t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295167/ https://www.ncbi.nlm.nih.gov/pubmed/37370658 http://dx.doi.org/10.3390/bioengineering10060727 |
_version_ | 1785063355860385792 |
---|---|
author | Guo, Mengqin Peng, Tingting Wu, Chuanbin Pan, Xin Huang, Zhengwei |
author_facet | Guo, Mengqin Peng, Tingting Wu, Chuanbin Pan, Xin Huang, Zhengwei |
author_sort | Guo, Mengqin |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) refers to chronic progressive fibrotic interstitial pneumonia. It is called a “tumor-like disease” and cannot be cured using existing clinical drugs. Therefore, new treatment options are urgently needed. Studies have proven that ferroptosis is closely related to the development of IPF, and ferroptosis inhibitors can slow down the occurrence of IPF by chelating iron or reducing lipid peroxidation. For example, the ferroptosis inhibitor deferoxamine (DFO) was used to treat a mouse model of pulmonary fibrosis, and DFO successfully reversed the IPF phenotype and increased the survival rate of mice from 50% to 90%. Given this, we perceive that the treatment of IPF by delivering ferroptosis inhibitors is a promising option. However, the delivery of ferroptosis inhibitors faces two bottlenecks: low solubility and targeting. For one thing, we consider preparing ferroptosis inhibitors into nanomedicines to improve solubility. For another thing, we propose to deliver nanomedicines through pulmonary drug-delivery system (PDDS) to improve targeting. Compared with oral or injection administration, PDDS can achieve better delivery and accumulation in the lung, while reducing the systemic exposure of the drug, and is an efficient and safe drug-delivery method. In this paper, three possible nanomedicines for PDDS and the preparation methods thereof are proposed to deliver ferroptosis inhibitors for the treatment of IPF. Proper administration devices and challenges in future applications are also discussed. In general, this perspective proposes a promising strategy for the treatment of IPF based on inhalable nanomedicines carrying ferroptosis inhibitors, which can inspire new ideas in the field of drug development and therapy of IPF. |
format | Online Article Text |
id | pubmed-10295167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102951672023-06-28 Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis Guo, Mengqin Peng, Tingting Wu, Chuanbin Pan, Xin Huang, Zhengwei Bioengineering (Basel) Perspective Idiopathic pulmonary fibrosis (IPF) refers to chronic progressive fibrotic interstitial pneumonia. It is called a “tumor-like disease” and cannot be cured using existing clinical drugs. Therefore, new treatment options are urgently needed. Studies have proven that ferroptosis is closely related to the development of IPF, and ferroptosis inhibitors can slow down the occurrence of IPF by chelating iron or reducing lipid peroxidation. For example, the ferroptosis inhibitor deferoxamine (DFO) was used to treat a mouse model of pulmonary fibrosis, and DFO successfully reversed the IPF phenotype and increased the survival rate of mice from 50% to 90%. Given this, we perceive that the treatment of IPF by delivering ferroptosis inhibitors is a promising option. However, the delivery of ferroptosis inhibitors faces two bottlenecks: low solubility and targeting. For one thing, we consider preparing ferroptosis inhibitors into nanomedicines to improve solubility. For another thing, we propose to deliver nanomedicines through pulmonary drug-delivery system (PDDS) to improve targeting. Compared with oral or injection administration, PDDS can achieve better delivery and accumulation in the lung, while reducing the systemic exposure of the drug, and is an efficient and safe drug-delivery method. In this paper, three possible nanomedicines for PDDS and the preparation methods thereof are proposed to deliver ferroptosis inhibitors for the treatment of IPF. Proper administration devices and challenges in future applications are also discussed. In general, this perspective proposes a promising strategy for the treatment of IPF based on inhalable nanomedicines carrying ferroptosis inhibitors, which can inspire new ideas in the field of drug development and therapy of IPF. MDPI 2023-06-17 /pmc/articles/PMC10295167/ /pubmed/37370658 http://dx.doi.org/10.3390/bioengineering10060727 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Perspective Guo, Mengqin Peng, Tingting Wu, Chuanbin Pan, Xin Huang, Zhengwei Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis |
title | Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis |
title_full | Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis |
title_fullStr | Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis |
title_full_unstemmed | Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis |
title_short | Engineering Ferroptosis Inhibitors as Inhalable Nanomedicines for the Highly Efficient Treatment of Idiopathic Pulmonary Fibrosis |
title_sort | engineering ferroptosis inhibitors as inhalable nanomedicines for the highly efficient treatment of idiopathic pulmonary fibrosis |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295167/ https://www.ncbi.nlm.nih.gov/pubmed/37370658 http://dx.doi.org/10.3390/bioengineering10060727 |
work_keys_str_mv | AT guomengqin engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis AT pengtingting engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis AT wuchuanbin engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis AT panxin engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis AT huangzhengwei engineeringferroptosisinhibitorsasinhalablenanomedicinesforthehighlyefficienttreatmentofidiopathicpulmonaryfibrosis |